news Mitochondrial enzyme found to block ferroptosis, presenting cancer target 13 May 2021 | By Victoria Rees (Drug Target Review) The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) can block cell death, new research has shown, making it a cancer drug target.
news Study defines small-cell lung cancer subtypes and therapeutic vulnerabilities 22 January 2021 | By Victoria Rees (Drug Target Review) Researchers have identified four unique subtypes of small-cell lung cancer (SCLC) following the characterisation of cell types.
news NIK could be key to enhancing the effects of immunotherapy 6 January 2021 | By Hannah Balfour (Drug Target Review) Immunology study shows that NF-kappa B-inducing kinase (NIK) is critical to T cell metabolism and the antitumour immune response.
news HDAC3 inhibitors: a potential treatment for non-Hodgkin lymphomas? 9 January 2020 | By Hannah Balfour (Drug Target Review) A murine study found histone deacetylase 3 (HDAC3) inhibitors reverse epigenetic changes caused by CREBBP mutations found in lymphomas and could be developed into a novel therapy.
news Stephen Hahn nominated to be new FDA commissioner 5 November 2019 | By Rachael Harper (Drug Target Review) President Trump has announced his intent to nominate Stephen Hahn as Commissioner of Food and Drugs at the Department of Health and Human Services.
news Promising drug developed for ovarian and pancreatic cancers 22 July 2019 | By Drug Target Review An antibody has been developed to block a protein secreted by the cells surrounding ovarian and pancreatic cancer tumours.
news New potential liver cancer treatment found with biomarker-guided strategy 16 July 2019 | By European Pharmaceutical Review A cellular pathway may reduce side effects and extend immunotherapy duration in patients with the most common form of liver cancer.
news FGL2 protein may be an effective target for GBM 28 January 2019 | By Drug Target Review Researchers have discovered an immune regulator that appears to dictate glioblastoma progression by shutting down immune surveillance...
news PKCδ enzyme linked to therapy resistance in lung cancer 11 December 2018 | By Drug Target Review The enzyme protein kinase C delta (PKCδ) found in NSCLC tumors prevents tyrosine kinase inhibitors (TKIs) from forestalling cancer...